Comparable stake leader
Ph.D. Noubar B. Afeyan
SEC ownership of Rubius Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001709401.
Disclosed value leader
—
Comparable rows
0/13
Latest evidence
01 Feb 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Ph.D. Noubar B. Afeyan
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
01 Feb 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001709401
- Issuer location
- Foxboro, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Rubius Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ph.D. Noubar B. Afeyan
Disclosed value leader
—
Comparable rows
0/13
Latest evidence
01 Feb 2023
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
13 rows are not safely comparable across share classes.
Showing 1-8 of 13 holder rows.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 13 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ph.D. Noubar B. Afeyan's linked filing trail.
Detailed SEC evidence table Showing 1-8 of 13 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ph.D. Noubar B. Afeyan |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
—
25,000 shares
|
— | 12 May 2022 |
| David R. Epstein |
3/4/5
Director
|
—
class O/S missing
|
—
499,762 shares
|
— | 12 May 2022 |
| Maiken Keson-Brookes |
3/4/5
CLO & Corp. Secretary
|
—
mixed-class rows
|
—
183,593 shares
mixed-class rows
|
— | 29 Jan 2022 |
| Jose Carmona |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
—
178,250 shares
mixed-class rows
|
— | 31 Jan 2022 |
| Pablo J. Cagnoni |
3/4/5
Director
|
—
mixed-class rows
|
—
141,082 shares
mixed-class rows
|
— | 01 Feb 2023 |
| Susanne Schaffert |
3/4/5
Director
|
—
class O/S missing
|
—
50,000 shares
|
— | 29 Jul 2022 |
| Laurence A. Turka |
3/4/5
Chief Scientific Officer
|
—
mixed-class rows
|
—
44,266 shares
mixed-class rows
|
— | 29 Jan 2023 |
| Anne Prener |
3/4/5
Director
|
—
class O/S missing
|
—
25,000 shares
|
— | 12 May 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 21 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Rubius Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
David R. Epstein
Net 12M change
$0
Latest report
24 Feb 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| David R. Epstein | Director | Mixed | 12 May 2022 | |||
| Ph.D. Noubar B. Afeyan | Director, 10%+ Owner | Mixed | 12 May 2022 | |||
| Francis M. Cuss | Director | Mixed | 12 May 2022 | |||
| Natalie C. Holles | Director | Mixed | 12 May 2022 | |||
| Jonathan Symonds | Director | Mixed | 12 May 2022 | |||
| Maiken Keson-Brookes | CLO & Corp. Secretary | Mixed | 29 Jan 2022 | |||
| Anne Prener | Director | Mixed | 12 May 2022 | |||
| Dannielle Appelhans | CEO and President | Mixed | 24 Feb 2023 | |||
| Laurence A. Turka | Chief Scientific Officer | Mixed | 29 Jan 2023 | |||
| Pablo J. Cagnoni | Director | Mixed | 01 Feb 2023 | |||
| Catherine A. Sohn | Director | Mixed | 12 May 2022 | |||
| Jose Carmona | Chief Financial Officer | Mixed | 31 Jan 2022 | |||
| Michael Rosenblatt | Director | Mixed | 12 May 2022 | |||
| Susanne Schaffert | Director | Mixed | 29 Jul 2022 |
Recent insider transactions for Rubius Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.